Corporate News     20-Apr-20
Alembic Pharmaceuticals receives USFDA tentative approval for Alcaftadine Ophthalmic Solution
Alembic Pharmaceuticals announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Alcaftadine Ophthalmic Solution, 0.25%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Lastacaft Ophthalmic Solution, 0.25%, of Allergan, Inc. (Allergan). Alcaftadine Ophthalmic Solution is an H1 histamine receptor antagonist indicated for the prevention of itching associated with allergic conjunctivitis.

Alcaftadine Ophthalmic Solution, 0.25% has an estimated market size of US$ 7 million for twelve months ending December 2019 according to IQVIA.

Alembic has a cumulative total of 120 ANDA approvals (107 final approvals and 13 tentative approvals) from USFDA.

Previous News
  Alembic Pharmaceuticals reports consolidated net profit of Rs 120.60 crore in the June 2023 quarter
 ( Results - Announcements 04-Aug-23   14:15 )
  Alembic Pharmaceuticals receives USFDA approval for various products
 ( Corporate News - 09-May-24   09:01 )
  Alembic Pharma gains on USFDA nod for Fluorouracil injection
 ( Hot Pursuit - 06-Mar-23   11:13 )
  Alembic Pharma's Panelav facility gets EIR from USFDA
 ( Hot Pursuit - 09-Dec-22   14:23 )
  Alembic Pharma karkhadi facility gets two USFDA observations
 ( Hot Pursuit - 25-Mar-23   12:35 )
  USFDA issues EIR for Alembic's Panelav oncology injectable formulation unit
 ( Corporate News - 09-Dec-22   13:39 )
  Alembic Pharmaceuticals receives USFDA final approval for Arformoterol Tartrate Inhalation Solution
 ( Corporate News - 11-May-22   11:39 )
  USFDA inspects Alembic Pharmaceuticals' Karkhadi unit
 ( Corporate News - 24-Mar-23   16:33 )
  Alembic Pharma gets USFDA nod for Nifedipine tablets
 ( Hot Pursuit - 21-Nov-22   11:14 )
  Alembic Pharmaceuticals to declare Quarterly Result
 ( Corporate News - 21-Apr-22   10:40 )
  Rhizen receives USFDA IND approval for oral anti-viral drug for treatment of COVID
 ( Corporate News - 02-Dec-20   11:14 )
Other Stories
  High Energy Batteries (India) to discuss results
  06-Jul-24   10:29
  Havells India schedules board meeting
  06-Jul-24   10:29
  Axis Bank announces board meeting date
  06-Jul-24   10:29
  Mastek to conduct board meeting
  06-Jul-24   10:29
  Oriental Hotels to conduct board meeting
  06-Jul-24   10:29
  Milkfood schedules AGM
  06-Jul-24   10:28
  Transcorp International to table results
  06-Jul-24   10:28
  MRP Agro to convene board meeting
  06-Jul-24   10:28
  Thirumalai Chemicals to table results
  06-Jul-24   10:28
  Bajaj Healthcare schedules board meeting
  06-Jul-24   10:27
Back Top